Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin

British Journal of Pharmacology

Volumn 166, Issue 3, 2012, Pages 938-949

  Medina, Carlos ^a   Harmon, Shona ^a   Inkielewicz, Iwona ^b   Santos Martinez, Maria Jose ^a   Jones, Michael ^a   Cantwell, Paula ^a   Bazou, Despina ^a   Ledwidge, Mark ^c,d   Radomski, Marek W ^a   Gilmer, John F ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

aspirin; aspirin prodrugs; ST0702; tumour cell induced platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; ADENOSINE DIPHOSPHATE; DRUG METABOLITE; GELATINASE A; ISOSORBIDE 2 ASPIRINATE 5 NICOTINATE; PADGEM PROTEIN; ST 0702; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; DRUG TARGETING; FIBROSARCOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; THROMBOCYTE AGGREGATION; TUMOR CELL INDUCED PLATELET AGGREGATION; UPREGULATION; ZYMOGRAPHY;

ASPIRIN; BLOOD PLATELETS; CELL COMMUNICATION; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FLOW CYTOMETRY; HUMANS; ISOSORBIDE; MICROSCOPY, PHASE-CONTRAST; NIACIN; PHYSOSTIGMINE; PLATELET AGGREGATION; PRODRUGS;

EID: 84860851716     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01794.x     Document Type: Article

References (45)

1. Alonso-Escolano D, Strongin AY, Chung AW, Deryugina EI, Radomski MW, (2004). Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol 141: 241-252.
2. Alonso-Escolano D, Medina C, Cieslik K, Radomski A, Jurasz P, Santos-Martinez MJ, et al,. (2006). PKCδ mediates platelet-induced breast cancer cell invasion. J Pharmacol Exp Ther 18: 373-380.
3. Andrews RK, Berndt MC, (2004). Platelet physiology and thrombosis. Thromb Res 114: 447-453.
4. Armstrong RA, (1996). Platelet prostanoid receptors. Pharmacol Ther 72: 171-191.
5. Bastida E, Escolar G, Ordinas A, Jamieson GA, (1986). Morphometric evaluation of thrombogenesis by microvesicles from human tumor cell lines with thrombin-dependent (U87MG) and adenosine diphosphate-dependent (SKNMC) platelet-activating mechanisms. J Lab Clin Med 108: 622-627.
6. Bazou D, Santos-Martinez MJ, Medina C, Radomski MW, (2011). Elucidation of flow-mediated tumour cell-induced platelet aggregation using an ultrasound standing wave trap. Br J Pharmacol 162: 1577-1589.
7. Bosetti C, Gallus S, La Vecchia C, (2009). Aspirin and cancer risk: a summary review to 2007. Recent Results Cancer Res 181: 231-251.
8. Cha YI, DuBois RN, (2007). NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 58: 239-252.
9. Chan AT, Ogino S, Fuchs CS, (2009). Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302: 649-658.
10. Dunlap T, Abdul-Hay SO, Chandrasena REP, Hagos GK, Sinha V, Wang Z, et al,. (2008). Nitrates and NO-NSAIDs in cancer chemoprevention and therapy: in vitro evidence querying the NO donor functionality. Nitric Oxide 19: 115-124.
11. Elwood PC, Gallagher AM, Duthie GG, Mur LAJ, Morgan G, (2009). Aspirin, salicylates, and cancer. Lancet 373: 1301-1309.
12. Gachet C, (2001). Identification, characterization, and inhibition of the platelet ADP receptors. Int J Hematol 74: 375-381.
13. Gachet C, (2006). Regulation of platelet function by P2 receptors. Annu Rev Pharmacol Toxicol 46: 277-300.
14. Gachet C, (2008). P2 receptors, platelet function and pharmacological implications. Thromb Haemost 99: 466-472.
15. Gresele P, Momi S, (2006). Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc Drug Rev 24: 148-168.
16. Gupta GP, Massague J, (2004). Platelets and metastasis revisited: a novel fatty link. J Clin Invest 114: 1691-1693.
17. Heinmoller E, Weinel RJ, Heidtmann HH, Salge U, Seitz R, Schmitz I, et al,. (1996). Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines. J Cancer Res Clin Oncol 122: 735-744.
18. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE, (2010). Aspirin intake and survival after breast cancer. J Clin Oncol 28: 1467-1472.
19. Honn KV, Tang D, (1992). Hemostasis and malignancy: an overview. Cancer Metastasis Rev 11: 223-226.
20. Harmon S, Inkielewicz-Stepniak I, Jones M, Ledwidge M, Santos-Martinez MJ, Medina C, Radomski MW, Gilmer JF, (2012). Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets. J Pharm Pharmacol. 64: 77-89.
21. Jones M, Inkielewicz I, Medina C, Santos-Martinez MJ, Radomski A, Radomski MW, et al,. (2009). Isosorbide-based aspirin prodrugs: integration of nitric oxide releasing groups. J Med Chem 52: 6588-6598.
22. Jurasz P, Sawicki G, Duszyk M, Sawicka J, Miranda C, Mayers I, et al,. (2001). Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res 61: 376-382.
23. Jurasz P, North S, Venner P, Radomski MW, (2003). Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study. Thromb Res 112: 59-64.
24. Jurasz P, Alonso-Escolano D, Radomski MW, (2004). Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 143: 819-826.
25. Kim YJ, Borsig L, Han H-L, Varki NM, Varki A, (1999). Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am J Pathol 155: 461-472.
26. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G, (2011). Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer 105: 1107-1113.
27. Lebeau B, Chastang C, Muir JF, Vincent J, Massin F, Fabre C, (1993). No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The 'Petites Cellules' Group. Cancer 71: 1741-1745.
28. Lipton A, Scialla S, Harvey H, Dixon R, Gordon R, Hamilton R, et al,. (1982). Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. J Med 13: 419-429.
29. Medina C, Jurasz P, Santos-Martinez MJ, Jeong SS, Mitsky T, Chen R, et al,. (2006). Platelet aggregation-induced by Caco2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate. J Pharmacol Exp Ther 317: 739-745.
30. Moriarty LM, Lally MN, Carolan CG, Jones M, Clancy JM, Gilmer JF, (2008). Discovery of a 'true' aspirin prodrug. J Med Chem 51: 7991-7999.
31. Oleksowicz L, Dutcher JP, (1995). Adhesive receptors expressed by tumor cells and platelets: novel targets for therapeutic anti-metastatic strategies. Med Oncol 12: 95-102.
32. Opie LH, (2011). Aspirin in the prevention of cancer. Lancet 377: 1651.
33. Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T, et al,. (2005). Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol 146: 882-893.
34. Radomski M, Moncada S, (1983). An improved method for washing of human platelets with prostacyclin. Thromb Res 30: 383-389.
35. Radomski MW, Jenkins DC, Holmes L, Moncada S, (1991). Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res 51: 6073-6078.
36. Reilly M, Fitzgerald GA, (1993). Cellular activation by thromboxane A2 and other eicosanoids. Eur Heart J 14 (Suppl. K): 88-93.
37. Rickles FR, Levine MN, Dvorak HF, (2001). Abnormalities of hemostasis in malignancy. In:, Colman RF, Hirsh J, Marder VJ, Clowes AW, George JN, (eds). Hemostasis and Thrombosis Basic Principles and Clinical Practice, 4th edn. Lippincott Williams & Wilkins: Philadelphia, PA, pp. 1132-1152.
38. Rigas B, Williams JL, (2008). NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide 19: 199-204.
39. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW, (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377: 31-41.
40. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al,. (2003). A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890.
41. Serebruany V, Malinin A, Aradi D, Kuliczkowski W, Norgard NB, Boden WE, (2010). The in vitro effects of niacin on platlet biomarkers in human volunteers. Thromb Haemost 104: 311-317.
42. Shattil SJ, Kashiwagi H, Pampori N, (1998). Integrin signaling: the platelet paradigm. Blood 91: 2645-2657.
43. Trousseau A, (1865). Clinique Medicale de L'Hotel-Dieu Paris. New Sydenham Society: London, pp. 94-96.
44. Varki NM, Varki A, (2002). Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost 28: 53-66.
45. Wahrenbrock M, Borsig L, Le D, Varki N, Varki A, (2003). Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 112: 853-862.